Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 646

1.

Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection.

Warfield KL, Olinger G, Deal EM, Swenson DL, Bailey M, Negley DL, Hart MK, Bavari S.

J Immunol. 2005 Jul 15;175(2):1184-91.

2.

Functional CD8+ T cell responses in lethal Ebola virus infection.

Bradfute SB, Warfield KL, Bavari S.

J Immunol. 2008 Mar 15;180(6):4058-66.

4.

Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge.

Warfield KL, Swenson DL, Olinger GG, Kalina WV, Aman MJ, Bavari S.

J Infect Dis. 2007 Nov 15;196 Suppl 2:S430-7.

PMID:
17940980
5.

Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.

Wang D, Raja NU, Trubey CM, Juompan LY, Luo M, Woraratanadharm J, Deitz SB, Yu H, Swain BM, Moore KM, Pratt WD, Hart MK, Dong JY.

J Virol. 2006 Mar;80(6):2738-46.

6.

Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection.

Warfield KL, Swenson DL, Negley DL, Schmaljohn AL, Aman MJ, Bavari S.

Vaccine. 2004 Sep 3;22(25-26):3495-502.

PMID:
15308377
8.

Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of ebola virus GP DNA vaccines.

Dowling W, Thompson E, Badger C, Mellquist JL, Garrison AR, Smith JM, Paragas J, Hogan RJ, Schmaljohn C.

J Virol. 2007 Feb;81(4):1821-37. Epub 2006 Dec 6.

9.

IL-10 mediates suppression of the CD8 T cell IFN-gamma response to a novel viral epitope in a primed host.

Liu XS, Xu Y, Hardy L, Khammanivong V, Zhao W, Fernando GJ, Leggatt GR, Frazer IH.

J Immunol. 2003 Nov 1;171(9):4765-72.

10.

A mouse model to study immunity against pseudorabies virus infection: significance of CD4+ and CD8+ cells in protective immunity.

Bianchi AT, Moonen-Leusen HW, van Milligen FJ, Savelkoul HF, Zwart RJ, Kimman TG.

Vaccine. 1998 Oct;16(16):1550-8.

PMID:
9711803
11.

Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins.

Wilson JA, Bray M, Bakken R, Hart MK.

Virology. 2001 Aug 1;286(2):384-90.

12.

Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice.

Bengtsson KL, Song H, Stertman L, Liu Y, Flyer DC, Massare MJ, Xu RH, Zhou B, Lu H, Kwilas SA, Hahn TJ, Kpamegan E, Hooper J, Carrion R Jr, Glenn G, Smith G.

Vaccine. 2016 Apr 7;34(16):1927-35. doi: 10.1016/j.vaccine.2016.02.033. Epub 2016 Feb 24.

13.

Discovery of common marburgvirus protective epitopes in a BALB/c mouse model.

Kalina WV, Warfield KL, Olinger GG, Bavari S.

Virol J. 2009 Aug 27;6:132. doi: 10.1186/1743-422X-6-132.

14.
15.

Comparison of the protective efficacy of DNA and baculovirus-derived protein vaccines for EBOLA virus in guinea pigs.

Mellquist-Riemenschneider JL, Garrison AR, Geisbert JB, Saikh KU, Heidebrink KD, Jahrling PB, Ulrich RG, Schmaljohn CS.

Virus Res. 2003 Apr;92(2):187-93.

PMID:
12686428
16.
17.
19.

CD4-directed peptide vaccination augments an antitumor response, but efficacy is limited by the number of CD8+ T cell precursors.

Hanson HL, Kang SS, Norian LA, Matsui K, O'Mara LA, Allen PM.

J Immunol. 2004 Apr 1;172(7):4215-24.

Supplemental Content

Support Center